+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Open-Angle Glaucoma Therapeutics Market by Drug Class, Therapy Type, Route of Administration - Global Forecast to 2030- Product Image
Open-Angle Glaucoma Therapeutics Market by Drug Class, Therapy Type, Route of Administration - Global Forecast to 2030- Product Image
Sale

Open-Angle Glaucoma Therapeutics Market by Drug Class, Therapy Type, Route of Administration - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666188
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Open-Angle Glaucoma Therapeutics Market grew from USD 9.35 billion in 2024 to USD 10.22 billion in 2025. It is expected to continue growing at a CAGR of 8.84%, reaching USD 15.55 billion by 2030.

Setting the Stage for Open-Angle Glaucoma Therapeutics

Open-angle glaucoma remains a leading cause of irreversible vision loss worldwide, driven by an aging population and heightened diagnostic awareness. This executive summary offers a concise yet comprehensive overview of the therapeutic landscape, highlighting the interplay between emerging innovations and enduring standards of care. It unpacks pivotal shifts in drug development, evolving regulatory frameworks, and crucial economic factors shaping the market.

By examining the trajectory of intraocular pressure-lowering agents, this overview underscores how treatment paradigms have transitioned from monotherapy staples to sophisticated combination regimens and novel mechanisms of action. Stakeholders will appreciate an integrated perspective, blending clinical advancements with market forces to reveal actionable insights. As you delve into each section, anticipate a blend of qualitative analysis and strategic commentary designed to inform leadership teams, pipeline strategists, and commercial planners.

This introduction sets the stage for a detailed exploration of transformative shifts, tariff implications, segmentation revelations, regional nuances, and company strategies-all framed within a robust research methodology. It invites decision-makers to engage with evidence-based findings and to envision a roadmap for sustained growth in the evolving glaucoma therapeutics arena.

Pioneering Innovations Redefining Therapeutic Pathways

The landscape of glaucoma treatment is undergoing a profound transformation driven by advances in pharmacology and patient-centric delivery systems. Over the past decade, the emergence of Rho kinase inhibitors has redefined the mechanism of intraocular pressure control, offering new hope for patients unresponsive to traditional therapies. Concurrently, sustained-release implants and micropump technologies are gaining traction, promising improved adherence and reduced dosing frequency.

Digital health integrations, including remote tonometry and AI-driven imaging analysis, are enhancing early detection and personalized management, effectively bridging gaps in patient monitoring. Precision medicine approaches are emerging as prescribers leverage genetic and biomarker data to optimize therapeutic regimens. These shifts are complemented by advancements in fixed-dose combinations that aim to maximize efficacy while minimizing ocular surface toxicity.

Taken together, these innovations signal a paradigm shift from one-size-fits-all treatments toward a multifaceted, patient-tailored model of care. Understanding these transformative currents is essential for industry leaders seeking to navigate competitive pressures and capitalize on growth opportunities within the open-angle glaucoma sector.

Navigating Tariff-Driven Supply Chain Shifts in 2025

The impending cumulative tariffs in the United States slated for implementation in 2025 are poised to exert material pressure on the glaucoma therapeutics supply chain. Many active pharmaceutical ingredients and specialized excipients are sourced through cross-border partnerships; elevated import duties will inevitably increase production costs and force a recalibration of pricing strategies. Manufacturers dependent on overseas API manufacturing must consider reshoring or forging new trade alliances to mitigate exposure.

Pharmaceutical companies operating in a high-cost environment may encounter margin compression, prompting strategic shifts toward value-based contracting with payers and health systems. For tiered distribution networks, additional customs fees could ripple through wholesale pricing, potentially dampening patient access initiatives. Conversely, domestic API producers stand to benefit from reshored demand, creating an incentive for investment in local infrastructure.

Ultimately, the tariff landscape will command a proactive response, from contractual renegotiations to supply chain diversification. Organizations that anticipate these headwinds and adopt agile sourcing models will be best positioned to sustain competitive differentiation while safeguarding patient affordability.

Uncovering Therapeutic Niches through Segmentation Analysis

Deep segmentation analysis reveals critical nuances in therapeutic adoption and pipeline prioritization. When viewed through the lens of drug class, the market is anchored by prostaglandin analogues, with bimatoprost and latanoprost serving as foundational agents; tafluprost and travoprost drive incremental growth, while fixed-dose combinations marry beta blockers and carbonic anhydrase inhibitors to augment efficacy. Rho kinase inhibitors are carving out a niche among patients with refractory pressure, and alpha agonists continue to offer an alternative mechanism when first-line therapies falter.

Examining therapy type uncovers the rising influence of combination regimens, particularly those pairing beta blockers with prostaglandin analogues or carbonic anhydrase inhibitors with betaxolol. These dual-mechanism strategies address adherence challenges and reduce ocular surface toxicity. Monotherapy remains prevalent in newly diagnosed cases, leveraging established safety profiles to guide initial treatment decisions.

Route-of-administration segmentation highlights topical formulations as the primary delivery system, supported by oral agents for adjunctive control and emerging intravenous protocols in acute care settings. This multifaceted segmentation framework provides a strategic foundation for product positioning, clinical trial design, and go-to-market tactics across diverse patient cohorts.

Decoding Regional Market Dynamics and Opportunities

Regional dynamics are reshaping growth trajectories and competitive intensity across the globe. In the Americas, high reimbursement rates and robust clinical infrastructure sustain rapid uptake of premium therapies, including advanced prostaglandin analogues and fixed-dose combinations. Market participants face stringent regulatory scrutiny but benefit from predictable pricing frameworks that reward innovation.

Within Europe, Middle East & Africa, divergent regulatory pathways and fragmented payor landscapes present both obstacles and opportunities. While centralized approvals streamline access in parts of Europe, localized negotiation processes in the Middle East and Africa region require customized market entry strategies. Value demonstration and real-world evidence are pivotal to securing formulary placement.

Asia-Pacific stands out as the fastest-growing region, driven by demographic trends, expanding healthcare budgets, and rising glaucoma awareness. China and India are focal points for both originator and generic competition, prompting multinational players to tailor pricing and distribution models to local cost sensitivities. Emerging markets throughout Southeast Asia offer greenfield prospects for innovative delivery systems and patient education programs.

Competitive Landscape Shaped by Innovation and Alliances

The competitive landscape is characterized by a blend of established pharmaceutical giants and agile biotechs advancing novel mechanisms of action. Leading innovators have fortified their portfolios through strategic alliances, expanding into Rho kinase inhibitor development and sustained-release platforms. Mid-sized companies are differentiating through niche pipeline assets, targeting patients unresponsive to first-line therapies.

Recent product launches have underscored the importance of real-world data to validate both safety and adherence benefits. Organizations with robust pharmacovigilance networks are leveraging these insights to negotiate premium reimbursement. Meanwhile, manufacturers focusing on fixed-dose combinations are gaining physician preference by simplifying treatment regimens and reducing ocular surface adverse effects.

Smaller entrants are capitalizing on digital engagement, deploying telehealth tools and adherence apps to support patient journeys. As M&A activity intensifies, established players are selectively acquiring promising candidates to bolster their late-stage pipelines. Investors and decision-makers must closely monitor alliances, clinical readouts, and regulatory milestones to identify shifting power centers within the open-angle glaucoma market.

Strategic Imperatives for Market Leadership

Industry leaders should prioritize investments in emerging modalities that promise differentiated efficacy, such as Rho kinase inhibitors and sustained-release implants. Developing versatile manufacturing footprints will mitigate tariff-related risks while enhancing supply resilience. Companies are advised to pursue value-based contracting models that align pricing with clinical outcomes, thereby addressing payer demands for cost-effectiveness.

Tailored market entry strategies should integrate real-world evidence generation early in development to support reimbursement discussions, especially in fragmented regions. Embracing digital health solutions can elevate patient engagement and adherence, reinforcing brand loyalty. Collaboration with local partners in high-growth Asia-Pacific markets will unlock distribution networks and accelerate uptake.

Finally, streamlined regulatory pathways and targeted M&A can expedite access to novel assets. By adopting a proactive, evidence-driven approach, stakeholders will not only safeguard margins but also drive sustainable growth amid evolving market pressures.

Robust Multi-Method Research Framework

This report synthesizes a rigorous multi-method research framework combining primary interviews with key opinion leaders, ophthalmologists, and payers alongside comprehensive secondary analysis of peer-reviewed journals, patent filings, and regulatory databases. Data triangulation was employed to validate market trends and ensure consistency across sources. Segmentation analyses were constructed using established classification schemas for drug class, therapy type, and administration route, refined through expert validation.

Quantitative modelling incorporated historical uptake curves and tariff schedules to assess economic impacts, while qualitative insights were drawn from in-depth stakeholder consultations. Regional case studies provided context for market entry considerations, and competitive intelligence was derived from company disclosures, clinical trial registries, and transaction databases. Rigorous editorial review and quality checks were conducted to maintain data integrity and analytical robustness throughout.

Charting a Resilient Path Forward for Glaucoma Care

The open-angle glaucoma therapeutics market stands at a pivotal juncture, where innovative modalities intersect with shifting economic and regulatory landscapes. Stakeholders must balance the promise of advanced drug classes and delivery systems against mounting cost pressures from impending tariffs and regional reimbursement complexities. Success will hinge on the ability to leverage segmentation insights, embrace digital health, and forge strategic partnerships that accelerate access to novel therapies.

In this dynamic environment, those who anticipate market shifts and act decisively will capture the most significant growth opportunities. By integrating real-world evidence into development plans, optimizing supply chains for greater agility, and tailoring strategies to diverse regional markets, organizations can secure a competitive edge. The strategic road map outlined here serves as a guide for informed decision-making and sustainable value creation in the evolving glaucoma space.

Moving forward, continuous monitoring of clinical breakthroughs, economic policies, and competitive maneuvers will be essential. The onus now lies on industry leaders to transform insights into actions that elevate patient outcomes and drive commercial success.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Alpha Agonists
    • Beta Blockers
      • Betaxolol
      • Metipranolol
      • Timolol
    • Carbonic Anhydrase Inhibitors
    • Fixed Dose Combinations
    • Prostaglandin Analogues
      • Bimatoprost
      • Latanoprost
      • Tafluprost
      • Travoprost
    • Rho Kinase Inhibitors
  • Therapy Type
    • Combination Therapy
      • Beta Blocker And Prostaglandin
      • Carbonic Anhydrase Inhibitor And Beta Blocker
    • Monotherapy
  • Route Of Administration
    • Intravenous
    • Oral
    • Topical
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Aerie Pharmaceuticals, Inc.
  • Alcon Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Open-Angle Glaucoma Therapeutics Market, by Drug Class
8.1. Introduction
8.2. Alpha Agonists
8.3. Beta Blockers
8.3.1. Betaxolol
8.3.2. Metipranolol
8.3.3. Timolol
8.4. Carbonic Anhydrase Inhibitors
8.5. Fixed Dose Combinations
8.6. Prostaglandin Analogues
8.6.1. Bimatoprost
8.6.2. Latanoprost
8.6.3. Tafluprost
8.6.4. Travoprost
8.7. Rho Kinase Inhibitors
9. Open-Angle Glaucoma Therapeutics Market, by Therapy Type
9.1. Introduction
9.2. Combination Therapy
9.2.1. Beta Blocker and Prostaglandin
9.2.2. Carbonic Anhydrase Inhibitor and Beta Blocker
9.3. Monotherapy
10. Open-Angle Glaucoma Therapeutics Market, by Route of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Topical
11. Americas Open-Angle Glaucoma Therapeutics Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Open-Angle Glaucoma Therapeutics Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Open-Angle Glaucoma Therapeutics Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. AbbVie Inc.
14.3.2. Novartis AG
14.3.3. Pfizer Inc.
14.3.4. Merck & Co., Inc.
14.3.5. Santen Pharmaceutical Co., Ltd.
14.3.6. Aerie Pharmaceuticals, Inc.
14.3.7. Alcon Inc.
14.3.8. Viatris Inc.
14.3.9. Teva Pharmaceutical Industries Ltd.
14.3.10. Sun Pharmaceutical Industries Ltd.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 46. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 47. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 48. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 49. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 50. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 51. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 53. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 54. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 55. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 56. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 57. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 77. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 79. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 80. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 81. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 82. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 85. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 86. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 87. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 88. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 91. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 92. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 93. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 94. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 97. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 98. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 99. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 100. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 102. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 103. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 104. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 105. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 106. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 109. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 110. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 111. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 112. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 115. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 116. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 117. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 118. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 130. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 133. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 134. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 135. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 136. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 142. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 145. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 146. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 147. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 148. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. FINLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. FINLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 151. FINLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 152. FINLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 153. FINLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 154. FINLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. SWEDEN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. SWEDEN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 157. SWEDEN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 158. SWEDEN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 159. SWEDEN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 160. SWEDEN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. NIGERIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. NIGERIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 163. NIGERIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 164. NIGERIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 165. NIGERIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 166. NIGERIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. EGYPT OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. EGYPT OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 169. EGYPT OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 170. EGYPT OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 171. EGYPT OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 172. EGYPT OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. TURKEY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. TURKEY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 175. TURKEY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 176. TURKEY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 177. TURKEY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 178. TURKEY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. ISRAEL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. ISRAEL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. NORWAY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. NORWAY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 187. NORWAY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 188. NORWAY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 189. NORWAY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 190. NORWAY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. POLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. POLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 193. POLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 194. POLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 195. POLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 196. POLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. SWITZERLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. SWITZERLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 199. SWITZERLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 200. SWITZERLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 201. SWITZERLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 202. SWITZERLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 210. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 212. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 213. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 214. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 215. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. INDIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 217. INDIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 218. INDIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 219. INDIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 220. INDIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 221. INDIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. JAPAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. JAPAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 224. JAPAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 225. JAPAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 226. JAPAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 227. JAPAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. SOUTH KOREA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 235. SOUTH KOREA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 236. SOUTH KOREA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. THAILAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. THAILAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 248. THAILAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 249. THAILAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 250. THAILAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 251. THAILAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. PHILIPPINES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 253. PHILIPPINES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 254. PHILIPPINES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 255. PHILIPPINES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 256. PHILIPPINES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 257. PHILIPPINES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. MALAYSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 260. MALAYSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 261. MALAYSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 263. MALAYSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. SINGAPORE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 265. SINGAPORE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 266. SINGAPORE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 267. SINGAPORE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 268. SINGAPORE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 269. SINGAPORE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. VIETNAM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 271. VIETNAM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 272. VIETNAM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 273. VIETNAM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 274. VIETNAM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 275. VIETNAM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. TAIWAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 277. TAIWAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 278. TAIWAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2030 (USD MILLION)
TABLE 279. TAIWAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 280. TAIWAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 281. TAIWAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
TABLE 283. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

Companies Mentioned

The companies profiled in this Open-Angle Glaucoma Therapeutics market report include:
  • AbbVie Inc.
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Aerie Pharmaceuticals, Inc.
  • Alcon Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages193
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 10.22 Billion
Forecasted Market Value ( USD ) by 2030 $ 15.55 Billion
Compound Annual Growth Rate8.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Glaucoma Therapeutics Market Report by Drug Class, Indication, End User, and Region 2024-2032 - Product Image

Glaucoma Therapeutics Market Report by Drug Class, Indication, End User, and Region 2024-2032

  • Report
  • 135 Pages
  • Global
From
Open-angle Glaucoma Therapeutics Market 2024-2028 - Product Image

Open-angle Glaucoma Therapeutics Market 2024-2028

  • Report
  • 163 Pages
  • Global
From
Glaucoma Therapeutics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Indication, Distribution Channel, and Geography - Product Image

Glaucoma Therapeutics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Indication, Distribution Channel, and Geography

  • Report
  • 150 Pages
  • Global
From
Glaucoma Therapeutics - Global Strategic Business Report - Product Image

Glaucoma Therapeutics - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Open-Angle Glaucoma - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Open-Angle Glaucoma - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From

About the Open Angle Glaucoma Drugs Market

Open-angle glaucoma is a common type of glaucoma often characterized by an increase in intraocular pressure, which can lead to optic nerve damage and, if untreated, loss of vision. Open-angle glaucoma drugs are a subset of optical disorders drugs, aimed specifically at managing this condition. These medications typically strive to decrease intraocular pressure through various mechanisms, such as reducing the production of aqueous humor (the clear fluid in the eye) or increasing its outflow from the eye. The market comprises several classes of drugs, including prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors, and rho kinase inhibitors. Often these drugs are used in combination to achieve better control over eye pressure. Treatment for open-angle glaucoma is a crucial component of the broader optical disorders drugs market, which addresses a spectrum of conditions affecting vision, such as age-related macular degeneration, diabetic retinopathy, and cataracts. While therapies for these conditions can vary widely, the approach to managing open-angle glaucoma is more focused on pressure regulation within the eye to prevent or reduce damage to the optic nerve and maintain the patient's functional vision. Several key players in the open-angle glaucoma drugs market include Pfizer, Allergan (now part of AbbVie), Merck & Co., Novartis, and Santen Pharmaceutical. These companies have stayed at the forefront by offering a diverse portfolio of treatments and by investing in the development Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.